

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
February 2, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Announcement Regarding the Postponement of
the Re-election of the Board of Directors

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

The terms of the ninth session of the board of directors (the “Board”) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the “Company”) expired on February 1, 2026. Given that the preparation for re-election of the Board of the Company is underway, in order to maintain the continuity and stability of the relevant work, the re-election of the ninth session of the Board of the Company will be postponed, the terms of members of the Board, each special committee under the Board and the senior management of the Company will be correspondingly extended.

Before the completion of the re-election and appointment of the Board, members of the ninth session of the Board, members of each special committee under the Board and the senior management of the Company will continue to perform their respective duties in accordance with relevant laws and regulations, as well as the articles of association.

The postponement of the re-election of the Board of the Company will not affect the normal operation of the Company. The Company is proactively advancing the relevant procedures to complete the re-election of the Board promptly, and fulfill its corresponding obligations of information disclosure in a timely manner.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

February 2, 2026